The Tennessee Department of Health has now reported a total of 837,833 cases of COVID-19 across the state, up 1,270 cases on Wednesday from 16,525 new test results — a 6.9 percent positivity rate.
Of the total number of cases, 12,111 people have died — with 15 new deaths reported in the last 24 hours.
The number of active cases has remained flat in the past two weeks, with state health officials reporting that 13,176 individuals are currently infected with COVID.
The number of patients hospitalized within the state has also increased slightly, with 918 people now being treated for illness caused by the virus. In terms of capacity, the state reports that 13 percent of inpatient beds and 12 percent of ICU beds remain available. Nearly 78 percent of the state's ventilator supply is still available.
So far, 1,536,883 Tennessee residents have been fully immunized against COVID, which amounts to 22.5 percent of the state's total population of about 6,830,000. More than 274,000 doses of vaccine were administered during the past week, with the entire state having opened eligibility to residents 16 years and older.
A total of 3,666,873 doses have been administered across the state.
The Metro Public Health Department reported 92 new COVID cases on Wednesday. In total, 97,371 cases of COVID have been identified in Davidson County residents since the start of the pandemic. A little more than 1,500 of those are active infections. Of the total number of cases, 898 people have died.
In terms of hospital capacity, Middle Tennessee health systems report that 12 percent of inpatient beds and 9 percent of ICU beds remain available.
Nashville has fully immunized 24.1 percent of its total population and administered more than 422,000 doses thus far. The Davidson County population is an estimated 695,000.
Nashville research firm to study vaccine in kids 12 to 17 years old
Nashville-based Clinical Research Associates will begin a Phase III clinical trial May 3 for the COVID-19 vaccine developed by Novavax in healthy adolescents ages 12 to 17.
The clinical trials will measure safety, effectiveness, and immunogenicity of the vaccine in younger individuals than earlier clinical studies, which investigated the vaccine response only in individuals 16 and older.
The research firm will recruit approximately 150 volunteers for the effort. All must has parental consent to participate in the trial, according to a press release. Those interested can enroll here.
“Children can still catch, spread, and suffer the effects of COVID, and there is currently no available vaccine for this age group,” CRA President and CEO Linda Moore Schipani said in the release. “We are committed to protecting and improving the health and well-being of every child, we strictly abide by industry standards including Good Clinical Practices, and we go above and beyond to help our patients feel safe, healthy, and important. Every volunteer is contributing to a worthy cause: protecting others from COVID-19.”